J2993 Reteplase injection
Also known as: reteplase, retavase
Injection of reteplase (Retavase), a recombinant human tissue plasminogen activator (rt-PA) used as a thrombolytic agent for acute myocardial infarction.
In Plain Language
clot-busting medication; thrombolytic
Clinical Context
Used intravenously for acute myocardial infarction within 12 hours of symptom onset to dissolve coronary thrombosis.
RVU Information
CPT J2993 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2993?
CPT J2993 (Reteplase injection) is a J Codes (Drugs) code. Injection of reteplase (Retavase), a recombinant human tissue plasminogen activator (rt-PA) used as a thrombolytic agent for acute myocardial infarction.
How is J2993 administered?
CPT J2993 is administered by a healthcare provider, typically via injection or infusion. Used intravenously for acute myocardial infarction within 12 hours of symptom onset to dissolve coronary thrombosis. It is used by Cardiology, Emergency Medicine.
When is CPT J2993 used?
Used intravenously for acute myocardial infarction within 12 hours of symptom onset to dissolve coronary thrombosis.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.